Hologic, Inc. $HOLX Holdings Lowered by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ reduced its stake in Hologic, Inc. (NASDAQ:HOLX) by 71.4% in the third quarter, HoldingsChannel reports. The fund owned 45,529 shares of the medical equipment provider’s stock after selling 113,435 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Hologic were worth $3,071,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in HOLX. Winnow Wealth LLC acquired a new stake in Hologic in the third quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd raised its stake in shares of Hologic by 193.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 273 shares in the last quarter. Root Financial Partners LLC acquired a new stake in shares of Hologic in the third quarter valued at $27,000. SJS Investment Consulting Inc. lifted its holdings in shares of Hologic by 341.5% in the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 362 shares during the period. Finally, Loomis Sayles & Co. L P bought a new position in Hologic during the second quarter valued at about $33,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Morgan Stanley boosted their price target on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Evercore downgraded shares of Hologic from an “outperform” rating to an “in-line” rating and dropped their target price for the stock from $79.00 to $78.00 in a report on Monday, January 5th. Needham & Company LLC restated a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. Argus cut Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Two analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $78.42.

Hologic Stock Up 0.4%

HOLX stock opened at $75.43 on Friday. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $75.47. The company’s 50 day simple moving average is $74.92 and its 200-day simple moving average is $71.85. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. The firm has a market capitalization of $16.84 billion, a P/E ratio of 31.43, a P/E/G ratio of 2.24 and a beta of 0.72.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). Hologic had a return on equity of 19.58% and a net margin of 13.18%.The firm had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the business posted $0.87 EPS. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. As a group, equities research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.